middl
east
respiratori
syndrom
mer
first
describ
caus
novel
coronaviru
merscov
world
health
organ
decemb
report
confirm
case
merscov
infect
global
overal
mortal
rate
major
case
report
saudi
arabia
wherein
confirm
case
die
human
coronavirus
first
identifi
usual
caus
mild
upperrespiratori
tract
ill
first
confirm
case
merscov
report
saudi
arabia
merscov
infect
associ
signific
mortal
relat
virul
viru
natur
diseas
lack
effect
therapi
patient
merscov
develop
acut
respiratori
distress
syndrom
ard
high
risk
die
refractori
hypoxemia
multiorgan
failur
septic
shock
current
intervent
lung
protect
ventil
prone
ventil
neuromuscular
block
agent
shown
random
trial
improv
mortal
patient
ard
howev
patient
convent
measur
fail
maintain
adequ
oxygen
therefor
rescu
therapi
consid
differ
mode
ventil
inhal
pulmonari
vasodil
extracorpor
membran
oxygen
ecmo
anticip
difficulti
patient
recruit
studi
design
ethic
concern
affect
feasibl
conduct
random
clinic
trial
examin
efficaci
ecmo
popul
therefor
observ
studi
reason
altern
studi
aim
describ
effect
ecmo
rescu
therapi
patientimport
outcom
patient
sever
merscov
respons
larg
merscov
outbreak
saudi
ministri
health
implement
nation
ecmo
program
april
saudi
ecmo
program
provid
rapid
transport
chain
system
medevac
system
isol
intens
care
unit
icu
bed
venoven
vv
ecmo
machin
select
center
across
countri
ecmo
team
creat
avail
h
day
week
team
includ
intensivist
train
ecmo
cardiac
surgeon
perfusionist
ecmotrain
nurs
intensivist
ecmo
team
triag
call
center
base
predefin
criteria
wherein
patient
predetermin
candid
receiv
ecmo
criteria
elig
receiv
ecmo
base
extracorpor
life
support
organ
elso
guidelin
list
retrospect
identifi
patient
would
elig
ecmo
receiv
ecmo
program
avail
time
prior
april
intervent
ecmo
group
includ
five
main
ecmo
center
three
major
citi
saudi
arabia
program
initi
april
decemb
particip
hospit
accredit
joint
commiss
intern
close
icu
coverag
train
intensivist
obtain
ethic
approv
saudi
ministri
health
ethic
review
board
individu
center
ethic
board
patient
candid
receiv
ecmo
met
follow
criteria
laboratoryconfirm
merscov
accord
criteria
use
realtim
rtpcr
assay
target
region
merscov
genom
nasopharyng
swab
tracheal
aspir
bronchoalveolar
lavag
bal
admit
icu
invas
mechan
ventilationmet
ecmo
initi
criteria
sever
respiratori
failur
defin
andormurray
score
despit
optim
care
h
retent
mechan
ventil
despit
high
pplat
cm
none
follow
contraind
ecmo
mechan
ventil
high
set
pplat
daysrec
central
nervou
system
hemorrhageexist
nonrecover
termin
diseas
ecmo
group
includ
patient
met
criteria
receiv
ecmo
implement
ecmo
program
april
decemb
includ
patient
merscov
receiv
ecmo
period
control
group
patient
met
criteria
receiv
ecmo
period
prior
introduct
ecmo
program
prior
april
wean
ecmo
primarili
base
clinic
improv
demonstr
adequ
oxygen
ga
exchang
shown
vital
sign
blood
gase
chest
xray
decis
readi
patient
wean
ecmo
left
judgment
treat
clinician
ecmo
team
wean
process
follow
elso
criteria
follow
wean
start
decreas
flow
keep
sweep
maintain
remain
within
target
trial
clamp
cathet
keep
patient
ventil
appropri
set
attempt
design
electron
pretest
data
abstract
form
form
pilot
test
prior
data
collect
ensur
accuraci
reproduc
train
personnel
collect
data
particip
center
supervis
local
princip
investig
research
personnel
collect
data
patient
demograph
comorbid
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
laboratori
result
hemoglobin
concentr
white
blood
platelet
count
kidney
function
blood
gase
ventil
mode
set
intervent
use
treat
refractori
hypoxemia
prone
ventil
use
neuromuscular
block
drug
pulmonari
vasodil
vasoact
support
antimicrobi
antivir
therapi
steroid
use
primari
secondari
outcom
data
data
test
normal
use
test
repeatedmeasur
analysi
varianc
perform
fischer
exact
test
use
categor
data
independ
test
use
compar
continu
variabl
two
group
u
test
perform
compar
nonparametr
valu
two
group
data
express
median
interquartil
rang
iqr
rang
number
proport
mean
sd
appropri
volum
case
enough
allow
priori
power
analysi
howev
post
hoc
power
analysi
indic
current
sampl
size
patient
power
detect
absolut
differ
mortal
rate
type
error
power
valu
p
consid
statist
signific
eighti
patient
confirm
merscov
infect
admit
icu
particip
center
april
decemb
thirtyf
patient
met
elig
criteria
includ
analysi
ecmo
group
control
group
shown
tabl
baselin
characterist
similar
group
median
age
vs
year
mean
apach
ii
score
vs
statist
differ
p
p
respect
adjunct
therapi
use
group
ribavirin
use
significantli
often
ecmo
group
compar
control
group
vs
p
interferon
also
use
ecmo
cohort
compar
control
vs
p
use
steroid
similar
group
vs
p
day
one
elig
ecmo
patient
control
group
requir
hemodynam
support
norepinephrin
compar
ecmo
group
howev
group
similar
use
epinephrin
dobutamin
continu
renal
replac
therapi
crrt
mode
ventil
posit
endexpiratori
pressur
peep
neuromuscular
block
agent
tabl
alveolar
recruit
maneuv
use
one
patient
ecmo
group
none
patient
receiv
prone
ventil
throughout
day
patient
control
group
develop
renal
impair
significantli
lower
ratio
tabl
laboratori
valu
similar
group
tabl
howev
due
small
sampl
size
feasibl
adjust
confound
factor
ecmo
group
vv
mode
use
patient
via
percutan
cannul
approach
vascular
access
access
use
patient
access
use
case
ecmo
access
insert
cardiac
surgeon
case
cardiac
intensivist
remain
chest
xray
use
confirm
success
cannul
patient
transesophag
echocardiographi
tee
one
patient
blood
flow
l
revolut
per
minut
sweep
ga
among
ecmo
patient
mean
sd
respect
patient
citi
ecmo
center
situat
transport
via
ground
ambul
otherwis
patient
transport
via
fix
wing
medic
evacu
airplan
complic
report
patient
transport
ecmorel
mechan
complic
occur
patient
one
patient
develop
pneumothorax
treat
chest
tube
insert
two
patient
major
bleed
immedi
initi
ecmo
compar
control
group
ecmo
group
significantli
lower
inhospit
mortal
vs
p
longer
icu
stay
vs
day
p
tabl
fig
less
use
norepinephrin
day
p
better
oxygen
higher
ratio
throughout
day
tabl
retrospect
cohort
studi
found
ecmo
rescu
therapi
associ
lower
inhospit
mortal
better
oxygen
fewer
organ
failur
compar
histor
control
usual
care
patient
sever
merscov
howev
length
hospit
stay
possibl
explan
crisi
phase
patient
mechan
ventil
ward
icu
bed
full
possibl
could
contribut
similar
stay
hospit
group
although
elso
issu
guidelin
use
ecmo
patient
ard
guidelin
address
specif
diseas
context
difficult
gener
heterogen
ard
popul
therefor
conduct
observ
studi
report
efficaci
safeti
ecmo
patient
sever
merscov
infect
singl
case
report
literatur
look
ecmo
merscov
patient
gueri
et
al
describ
use
ecmo
two
patient
acut
respiratori
failur
secondari
merscov
infect
franc
patient
develop
sever
hypoxia
increas
oxygen
requir
lead
mechan
ventil
ecmo
use
one
patient
die
surviv
approxim
month
hospit
ecmo
use
respiratori
failur
report
variabl
surviv
rate
first
random
clinic
trial
rct
fail
prove
superior
ecmo
convent
manag
howev
sever
adult
respiratori
failur
cesar
trial
show
improv
surviv
patient
refer
earli
ecmo
center
largest
clinic
trial
investig
efficaci
earli
use
ecmo
patient
ard
despit
concern
trial
design
possibl
differ
steroid
use
ventil
strategi
result
contribut
increas
use
ecmo
worldwid
studi
observ
signific
differ
use
adjunct
therapi
except
ribavirin
use
ecmo
group
benefit
antivir
therapi
merscov
infect
remain
unclear
recent
korean
guidelin
publish
merscov
outbreak
south
korea
suggest
use
antivir
therapi
patient
sever
merscov
patient
respiratori
failur
infect
requir
use
ecmo
surviv
rate
vari
consider
studi
rang
larg
variat
surviv
rate
could
explain
differ
patient
baselin
characterist
sever
ill
one
studi
older
obes
diabet
immunocompromis
patient
found
higher
risk
develop
sever
merscov
infect
studi
two
group
compar
baselin
signific
differ
group
variabl
anoth
larg
observ
studi
examin
predictor
death
patient
underw
ecmo
found
creatinin
bilirubin
level
system
arteri
pressur
hematocrit
preecmo
hospit
length
stay
associ
higher
mortal
anoth
import
factor
center
experi
volum
case
could
contribut
variabl
surviv
rate
ecmo
use
recent
studi
barbaro
et
al
demonstr
center
ecmo
casesyear
better
surviv
rate
center
less
case
per
year
saudi
arabia
ecmo
avail
except
one
center
merscov
crisi
thereaft
ecmo
program
implement
therapeut
option
patient
refractori
hypoxemia
ecmo
intervent
run
tertiari
center
equip
icu
experienc
intensivist
perfusionist
receiv
train
ecmo
prior
start
program
although
ecmo
patient
receiv
ribavirin
interferon
therapi
believ
differ
impact
find
publish
report
therapi
limit
none
show
signific
improv
combin
largest
studi
date
publish
abstract
format
show
reduct
mortal
therefor
believ
imbal
cointervent
two
group
unlik
affect
estim
treatment
effect
regard
infect
control
issu
caregiv
safeti
ecmo
patient
organ
maintain
aggress
measur
appli
strictli
monitor
close
admiss
taken
airborn
isol
room
impact
contain
viru
plu
appli
univers
protect
person
measur
time
patient
encount
stringent
measur
report
caregiv
ecmo
patient
affect
knowledg
largest
studi
describ
outcom
patient
merscov
receiv
ecmo
sever
strength
studi
design
allow
us
compar
ecmo
case
control
group
similar
demograph
within
institut
also
collect
data
import
variabl
confound
conduct
adjust
analys
assess
impact
result
adher
strengthen
report
observ
studi
epidemiolog
strobe
guidelin
despit
strength
studi
sever
import
limit
first
retrospect
natur
studi
render
risk
bia
patient
control
group
die
may
explain
sever
ill
patient
ard
elig
otherwis
rule
possibl
select
bia
unabl
track
transfer
request
due
outbreak
crisi
time
leav
us
limit
inform
addit
patient
transfer
nonparticip
ecmo
center
therefor
baselin
preecmo
data
blood
gase
ventil
set
could
obtain
furthermor
due
insuffici
document
outbreak
crisi
circumst
abl
track
ecmo
request
referr
call
center
differ
cointervent
eg
antivir
therapi
influenc
unmeasur
confound
exclud
concern
address
rct
howev
conduct
rct
like
challeng
context
epidem
studi
design
compar
cost
intervent
although
import
outcom
could
help
clinician
stakehold
make
decis
lastli
small
sampl
size
limit
abil
perform
adequ
multivari
analysi
similar
ecmo
studi
difficult
determin
mortal
result
refractori
respiratori
failur
caus
like
septic
shock
organ
failur
summari
use
ecmo
associ
lower
mortal
patient
sever
merscov
infect
refractori
hypoxia
futur
random
trial
although
challeng
conduct
highli
need
confirm
disput
observ
data
avail
ecmo
could
consid
rescu
therapi
select
merscov
patient
refractori
hypoxemia
